Abstract: Mood depression is a common and serious complication after stroke. According to epidemiological studies, nearly 30% of stroke patients develop depression, either in the early or in the late stages after stroke. Although depression may affect functional recovery and quality of life after stroke, such condition is often ignored. In fact, only a minority of patients is diagnosed and even fewer are treated in the common clinical practice. Moreover, the real benefi ts of antidepressant (AD) therapy in post-stroke depression have not been fully clarifi ed. In fact, controlled studies on the effectiveness of ADs in post stroke depression (PSD) are relatively few. Today, data available suggest that ADs may be generally effective in improving mood, but guidelines for the optimal treatment and its length are still lacking.
The progressive decrease in stroke mortality observed in Western countries, in the last decades, and the subsequent increase of survivors with residual impairments and disabilities (Sarti et al 2000) , have been accompanied by a growing interest in factors that could interfere with functional outcome and quality of life (QoL). In light of this, a crucial role is played by post-stroke depression (PSD).
In particular, mood depression is considered as the strongest predictor of QoL in stroke survivors (Kim et al 1999; King 1996) . Moreover, PSD is associated with an increased disability ( Schwartz et al 1993; Herrmann et al 1998; Ramasubbu et al 1998; Kotila et al 1999; Pohjasvaara et al 2001) , increased cognitive impairment (Kauhanen et al 1999) , increased mortality, both on short and long term (Morris et al 1993; Schulz et al 2000; House et al 2001; Williams et al 2004) , increase risk of falls (Jorgensen et al 2002) and, fi nally, with worse rehabilitation outcome (Sinyor et al 1986; Paolucci et al 1999 Paolucci et al , 2001 van de Weg et al 1999; Gillen et al 2001) . Conversely, the absence of PSD in young adults is a signifi cant predictor of the ability to return to work (Neau et al 1998) . Moreover, an improvement of depressive symptoms has been associated with a better functional recovery (Chemerinski et al 2001) .
In spite of the relative large number of papers available on PSD, it is surprising to note that the attention of authors has been focused on epidemiological features and impact of PSD both on functional outcome and QoL than on possible therapeutic approaches.
This review concerns a literature evaluation on epidemiological and therapeutic aspects of PSD. Relevant articles related to depression and cerebrovascular diseases selected from computer-based search have been examined using the Medline database from 1975 to August 2007.
Epidemiological dimension and methodological problems
Today, in spite of the abundant literature available on this topic, it is still diffi cult to defi ne the real prevalence rate of PSD, essentially because of the weak concordance Paolucci across studies. This relevant variability arises not only from methodological problems of the investigations (differences in study populations and the timing of assessments) but also from the complexity in recognition, assessment, and diagnosis of depression.
In fact, as shown in the Table 1 , there is a large variability of diagnostic tools used for the detection of PSD. In fact, while most of the studies based the diagnosis on cutoff score in different rating scales, others followed a structured interview and the diagnostic standards defi ned by DSM (Diagnostic and statistical manual of mental disorders)-III, III-R, and IV, and some studies even based their assessment only on clinical fi ndings.
Moreover, assessment of depression in stroke survivors may be often laborious and the risk of inappropriate diagnosis (under-or overdiagnosing) is high (Fedoroff et al 1991) . In fact, PSD may not only be overdiagnosed because of somatic symptoms caused by medical illness, but also underdiagnosed, particularly in patients with cognitive impairment. Another problem, as observed by Schubert and coworkers (1992) , may be the inadequacy of physicians without a proper psychiatric training (Schubert et al 1992) . The correct attribution of somatic symptoms (psychomotor retardation, and disturbances in appetite, sleep, and sexual interest) to either PSD or stroke is a very relevant problem, because such symptoms may affect rating scales, as Hamilton Depression Rating Scale (HDRS), Montgomery Asberg Depression Rating Scale (MADRS), or Beck Depression Inventory (BDI), and also because they are among DSM criteria. It is important to remember that rating scales were designed to measure depression severity in primary depressive illness, rather than to diagnose depression, in particular for depression in comorbidity. Furthermore, DSM criteria for classifi cation of disorders, (temporal criteria, in particular) are not always satisfi ed for dysthymia and major depression. So, we found cases diagnosed as major depression even in reports on PSD in settings characterized by short hospital stay, such as stroke units (Kellermann et al 1999; Berg et al 2001) . Additionally, other relevant points, as evaluation-time after stroke (acute vs. chronic patients) and variability of the study setting (in-patients, outpatients, patients bedridden in rehabilitation structures, community), minimize the possibility of a generalization. Lastly, the problem of aphasia should be kept in mind. The exclusion of aphasic patients, because of the evident diffi culty in evaluating depressive symptoms, reported in several of studies examined, may be an important confounding variable (Carson et al 2000) . However, there is no concordance on frequency of PSD in aphasics, observed either in low (15%) (Damecour and Caplan 1991) , in middle (24%) (Laska et al 2007) and in high percentage (70% at 3 months and 62% at 12 months after stroke) of cases (Kauhanen et al 2000) .
A recent meta-analysis, evaluating data from studies conducted between 1977 and 2002, estimated the pooled frequency at 33% (95% confi dence interval, 29% to 36%) (Hackett et al 2005b) , even if with relevant differences across studies. In particular, the pooled estimate from the population-based studies was equal in the acute and medium-term phases (33%), with a slight increase to 34% in the long-term phase of recovery after stroke. Moreover, there were only slight differences in the pooled frequencies in the hospital-based (acute 36%, medium-term 32%, and long-term 34%) and rehabilitation-based studies (acute 30%, medium 36%, and long-term 34%) over time.
Studies available after the publication of that report confi rmed that PSD is generally observed in nearly one third of cases (Vataja et al 2004; Verdelho et al 2004; Paolucci et al 2006; Linden et al 2007; Townend et al 2007) . However, a certain degree of variability in the percentages was observed in those reports, too. In particular, the percentage of depression observed in the Sidney Stroke Study was lower than in the previous ones (Brodaty et al 2007) . Moreover, recent longitudinal studies observed not only that frequency PSD increases in prevalence over the initial weeks post-stroke, in particular within three months from stroke, despite an improvement in disability (Andersen et al 1994b; Aben et al 2003; Paolucci et al 2006) , but also that patients with early onset PSD were not necessarily affected later and vice versa, indicating the dynamic nature of PSD in the early stages.
Only few epidemiological data on vascular depression are available today. Vascular depression is a new diagnostic concept based on hypothesis that chronic ischemic damage is an important cause of depression in the elderly. This concept initially emerged from the fi nding that patients with late-onset depression had higher rate of encephalomalacia or hyperintensities observed with magnetic resonance imaging (MRI) compared with patients with early-onset depression (Hickie et al 1995) , and was later formulated by Alexopoulos and coworkers in 1997. These authors hypothesized that cerebrovascular disease can predispose, precipitate, or perpetuate a depressive syndrome in older adults (Alexopoulos et al 1997a) . Affected individuals display more apathy, retardation, and lack of insight, and less agitation and guilt than do elderly individuals who are depressed without vascular risk factors, on one hand, and also greater disability and cognitive impairment, on the other (Alexopoulos et al 1997b) . Mast and coworkers (Mast et al 2004) . In that study, a positive association was established between depression and increasing percentage of cerebrovascular risk factors (Mast et al 2004) . Furthermore, patients with depression and subcortical vascular lesions have poor response to antidepressants (Simpson et al 1998) , while might be effective dopamine acting agents or norepinephrine enhancing agents (Alexopoulos 2006) . Thus, should vascular depression be recognized as a separate psychiatric disorder or as a diagnostic subtype of major depressive disorder? Indeed, Alexopoulos refined the notion of vascular depression, proposing a depression executive dysfunction (DED) disorder of late-life, but only on the basis of clinical criteria and regardless the etiology (Alexopoulos 2001) , while Taylor and coworkers (2006) proposed subcortical ischemic depression as specifi c entity. On the other hand, while the former may be caused by vascular disease, the latter requires a subcortical vascular impairment. Further researches are needed to clarify these and other doubts.
Treatment studies
Although antidepressant (AD) drugs have been discovered many decades ago [monoamine oxidase inhibitors (MAOIs) in the 1950s, tricyclic antidepressant (TCA) imipramine in 1957 and fi rst selective serotonin reuptake inhibitor (SSRI), fl uoxetine in 1988], most patients today do not receive an effective specifi c treatment. The attitude that PSD is a natural and inevitable condition which is not important to treat seems still common. General opinion appears to be that depression improves if the patient's physical condition improves (Gustafson et al 1995) . Moreover, physicians are often reluctant to prescribe ADs to older patients with relevant physical illnesses (House et al 1989) , because of the perceived risk of side effects especially on the cardiovascular system, fear of drug interactions in multiple comorbidity, and poor experience of depression treatment in the elderly. However, a recent systematic review of 18 randomized controlled trials comparing any AD drug with placebo or no treatment in depressed adults with a specifi ed physical disorder showed that ADs cause improvement in depressive symptoms in patients with a wide range of physical diseases (Gill and Hatcher 1999) . In spite of these data, not only the studies on therapeutic approaches on PSD are relatively scarce, but also most of studies reported the effects of AD drugs only on mood disturbance. In fact, even if some authors suggested the favorable effect of AD drugs on functional recovery (Fedoroff and Robinson 1989) , there are only few studies that evaluated the impact of ADs on functional outcome and rehabilitation results (Reding et al 1986; Fedoroff and Robinson 1989; GonzalezTorrecillas et al 1995; Dam et al 1996; Miyai and Reding 1998; Paolucci et al 1999; Gainotti et al 2001; Paolucci et al 2001) . Table 2 reports the percentages of patients treated with ADs in papers regarding prevalence and clinical impact of PSD. 
The choice of optimal treatment
There is relatively little comparative information on how to make the choice of one AD over another, and none at all specifi c to PSD. Today, SSRIs are the recommended pharmacotherapy of PSD for their favorable tolerability profi le (Turner-Stokes and Hassan 2002; SPREAD 2005) . In fact, the affi nity of TCAs for a number of central receptors including muscarinic cholinergic and histaminergic receptors makes them not recommended as fi rst-line choice for treatment of PSD. Conversely, SSRIs have no affi nity for cholinergic or histaminergic receptors and thus are generally well tolerated, and do not have cardiovascular or sedative effects. However, the SSRIs are not entirely without side-effects. Gastrointestinal symptoms, headache, sexual dysfunction and insomnia are relatively common. Arguably, the most important difference between the SSRIs lays in their potential to cause drug-drug interactions through inhibition of cytochrome-P450 isoforms, which is different for each SSRI. Thus, fl uvoxamine is a potent CYP1A2 and CYP2C19 inhibitor, and a moderate CYP2C9, CYP2D6, and CYP3A4 inhibitor; fl uoxetine and paroxetine are potent CYP2D6 inhibitors; sertraline is a moderate CYP2D6 inhibitor; and citalopram has little effect on the major cytochrome-P450 isoforms (Hemeryck and Belpaire 2002) . So, fl uvoxamine (CYP1A2 inhibitor) can cause an increase of blood levels of theophyllin or caffeine, while paroxetine and fl uoxetine (CYP2D6 inhibitors) an increase of concentration of TCAs or atypical antipsychotics. Knowledge of the CYP-isoforms involved in the metabolism of the co-administered drug may help clinicians to predict and avoid potentially dangerous drug-drug interactions. Expected interactions can usually be managed by appropriate dose adjustments and titration of the drug. Importantly, the use of SSRIs has been associated with increased risk of bleeding complications (Skop and Brown 1996) 
Nonpharmacological management
Today, the main therapeutic approach of PSD, and in particularly in subacute phase after stroke, is essentially pharmacological. In fact, a psychotherapeutic intervention is not only expensive in terms of staff time and expertise, but also requires several weeks before showing any clinical improvement. This delay may be critical for the outcome in a time-limited course of rehabilitation. Therefore, in the common clinical practice, AD treatment is the most realistic solution, with psychotherapeutic intervention reserved for those in whom ADs are either inappropriate or not tolerated. Regarding the effectiveness of psychotherapeutic interventions, methodological limitations in existing research prevent a conclusion as any psychological intervention has empirical support for its effectiveness (Gordon and Hibbard 1997; Kneebone and Dunmore 2000) . On the other hand, cognitive behavioral therapy has shown some promising results that make it worthy of further exploration (Lincoln et al 1997; Lincoln and Flannaghan 2003) . 
Controlled pharmacological studies
Controlled studies on the effectiveness of ADs in PSD are relatively few, and they are essentially related to the use of TCAs or SSRIs (Table 3) . Data on usefulness of new dualcomponent ADs are still not available, to our knowledge.
In a recent Cochrane review, only 7 trials with AD, with a total of 615 patients, entered the meta-analyses (Hackett et al , 2005a . The results of meta-analyses showed that there was evidence of a improvement in depression rating scales, but not in terms of a complete remission of depression following stroke (Hackett et al , 2005a . However, some methodological aspects of this review have been criticized. In particular, Chen and Guo (2006) suggested that the overall effects of AD treatment in term of various depression scores would better be estimated by separating the pretreatment and post-treatment instead of calculating the mean differences. In this fashion, AD treatments were effective in patients after the stroke in term of reducing the symptoms of depression. Moreover, can the concept of remission be applied in patients with depression in comorbidity? In fact, the idea of remission refers to a return to symptom-free state or premorbid levels of functioning (Bakish 2001 ). Such a model for depression in comorbidity is obviously arduous to obtain, because of the presence of somatic symptoms.
In another recent review, involving six pharmacological studies, there was evidence that ADs signifi cantly improved mood, also in spite of a relevant number of dropouts due to side effects treatment, especially with heterocyclic ADs (Bhogal et al 2005) . So, it appears that both TCAs and SSRIs may be effective in the treatment of PSD, although the latter may produce fewer side-effects.
Two randomized, double-blinded, placebo-controlled studies have evaluated the effectiveness of nortriptyline, a tricyclic drug (Lipsey and Robinson 1984; Robinson et al 2000) . In the last one, the effectiveness of fl uoxetine was also assessed (Robinson et al 2000) . In both studies, a signifi cant improvement in depression symptoms was observed in the treated groups as compared to controls. In particular, in the fi rst study a mean baseline to endpoint improvement in HDRS score of 79% was observed in patients treated with nortriptyline as compared with an improvement of 40% in patients treated with placebo (Lipsey and Robinson 1984) . In the second study, the mean improvement in HDRS score was higher in depressed patients treated with nortriptyline (60% vs. 9% for patients treated with fl uoxetine and 30% with placebo) (Robinson et al 2000) . Furthermore, in the study by Robinson and colleagues (2000) , but not in that by Lipsey and Robinson (1984) , a better recovery in activities of daily living for nortriptyline group was observed. However, there was disagreement regarding drop-out rate: higher among those treated with nortriptyline (38%) in the study by Lipsey and Robinson (1984) , and among those treated with fl uoxetine (40%) in the study by Robinson and colleagues (2000) . However, in this latter study, such high drop-outs rate with fl uoxetine might have been due to the relative high dose (up to 40 mg per day) of fl uoxetine used (Robinson et al 2000) . Moreover, the results of this study fostered the discussion about methodological problems (Van de et al 2003) . Two double-blinded controlled studies have assessed the effectiveness of citalopram, a selective serotonin reuptake inhibitors (SSRI), the fi rst one vs. placebo and the second one vs. noradrenergic drug reboxetine (Andersen et al 1994a; Rampello et al 2004) . In both studies, citalopram showed good effi cacy and tolerability. In the fi rst study, a mean baseline to endpoint improvement in HDRS score of 45.5% was observed in patients treated with citalopram as compared with an improvement of 16% in patients treated with placebo. Although the drop-out rate was higher in citalopram group, the reported side effects were relatively well tolerated and transient (Andersen et al 1994a) . In the second trial, Rampello et al showed that citalopram exhibited greater effi cacy in anxious depressed patients, while reboxetine was more effective in retarded depressed patients. No severe side effects were recorded during the study. The drop-out rate was similar between groups, too (three for both treatment) (Rampello et al 2004) .
Four studies evaluated the effectives of fluoxetine, another SSRI agent, both on early and late phase after stroke (Robinson et al 2000; Wiart et al 2000; Fruehwald et al 2003; Choi-Kwon et al 2006) . The results of these studies are confl icting. In particular, while a positive action on mood even in early phase was observed by Wiart and colleagues (2000) , with a mean improvement in MADRS score of 58% for fl uoxetine group vs. 31% in placebo group, Fruehwald and coworkers (2003) observed such positive action only in the follow-up. Moreover, Choi-Kwon and colleagues (2006) found that fl uoxetine was effective only on emotional incontinence and anger proneness, while Robinson and coworkers (2000) above described a lower effectiveness in comparison with nortriptyline. The drop-out rates were also confl icting: Fruehwald observed no drop-outs during the treatment, Wiart only two (13.3%) in patients treated with fl uoxetine, while Choi-Kwon 19.7% in fl uoxetine group and 15.8% in placebo group (Wiart et al 2000; Fruehwald et al 2003; Choi-Kwon et al 2006) .
Sertraline, another SSRI AD, showed no advantage in comparison to placebo either on major depressive episode or minor depressive disorder (Murray et al 2005) . In fact, both groups improved substantially, with no differences between the treatments, either for major depressive episode or minor depressive disorder, or for short-or long-term antidepressant effect and neurologic outcome. However, the compound showed a signifi cantly positive effect only on QoL at follow-up at week 26. No serious side effects were observed (Murray et al 2005) .
A study by Lauritzen and coworkers (1994) compared the effi cacy of two TCAs, desipramine against imipramine, both drugs combined with mianserin. The doses of the drugs were fl exible, with side-effects as a guide during treatment. Imipramine treatment was more effective than desipramine in reducing depressive symptoms evaluated by means of Melancholia Scale, but not by means of HDRS. However, a large proportion (35%) of the sample was lost in the follow-up, particularly in the desipramine group (Lauritzen et al 1994) .
Lastly, Reding and colleagues (1986) evaluated the response of depressive symptoms to trazodone in a controlled trial vs. placebo. They showed that trazodone treated patients had a tendency to increase in autonomy in ADL measured by the Barthel index compared to patients treated with placebo. However, a high drop-out rate due to side effects was observed in both groups of patients. In particular, twelve patients discontinued the study: six patients from the trazodone group (4 sedation, 1 eye discomfort, 1 refusal), but also six patients in placebo group (4 sedation, 1 nausea, 1 dizziness). Moreover, because of the particular study design, it was not possible to compare the improvement in depression scores of both groups.
Other studies
There are other studies that evaluated the impact of different type of ADs on functional outcome and rehabilitation results. Today, AD therapy may be benefi cial to functional recovery but it cannot abolish the detrimental effect of depression on functional outcome (Gonzalez-Torrecillas et al 1995; Dam et al 1996; Miyai and Reding 1998; Gainotti et al 2001) .
Paolucci
In a nonrandomized study published in 1995, GonzalezTorrecillas and colleagues showed that treated PSD patients (with nortriptyline or fl uoxetine) had not only a better mood, but also a better functional and cognitive outcome compared to untreated PSD patients. Moreover, the study was nonblinded: fl uoxetine was given to patients with cardiac defects and nortriptyline to those without. Both drugs made similar gains in both mood and functional ability (GonzalezTorrecillas et al 1995) .
Some years later Gainotti and colleagues (2001) confi rmed that functional recovery of nontreated depressed patients was poorer than the nondepressed and the depressed but treated patients. Dam and colleagues (1996) observed that patients treated with fl uoxetine had better rehabilitation results in comparison with those of patients treated with norepinephrine reuptake blocker maprotiline or placebo. These effects were not related to the specifi c antidepressant action. Moreover, both groups treated with Ads showed a signifi cant baseline to endpoint mean improvement in HDRS score (fl uoxetine 30%, maprotiline 18%). Mean improvement in placebo group was 12%.
This favorable role of fl uoxetine on functional status was confi rmed also by another study, in which patients treated with fl uoxetine or trazodone showed a better improvement on functional independence measure compared with patients treated with desipramine (Miyai and Reding 1998) .
Since serotonin (5-HT) stimulates motor function, there are some studies that investigated the hypothesis that a pharmacological potentiation of 5-HT neurotransmission may improve motor function in healthy subjects and recovery in poststroke patients (Pariente et al 2001; Loubinoux et al 2002) . In particular, in a double-blind, crossover, placebocontrolled study on 8 patients with pure motor hemiparesis, a single dose of fl uoxetine was able to signifi cantly improve motor skills of the affected side (Pariente et al 2001) . However, other experimental reports (after focal ischemia in rats) did not confi rm these adjuvant action of fl uoxetine on recovery of motor function (Windle and Corbett. 2005) .
ADs may reduce post stroke mortality. In a 9 year followup study, treatment with fl uoxetine or nortriptyline for 12 weeks during the fi rst 6 months after stroke signifi cantly increased the survival of both depressed and nondepressed patients (Jorge et al 2003) .
Lastly, there are few studies on the usefulness of new dual-agents SNRIs (serotonin and norepinephrine reuptake inhibitors), as venlafaxine or milnacipran and duloxetine (Dahmen et al 1999; Yamakawa et al 2005) , but methodological problems (open-label studies and with small case-series) reduce the power of these data.
Prevention of PSD
A recent Cochrane review, evaluating data from nine trials (11 comparisons) involving different pharmaceutical agents, and three trials of psychotherapy, found no clear effect of either pharmacotherapy or psychotherapy on the prevention of depressive illness or disability . Moreover, data from a more recent trial showed that sertraline treatment, 50 mg/day, had no advantage in comparison to placebo in preventing PSD (Almeida et al 2006) .
A more recent meta-analysis published in 2007, evaluating 10 randomized clinical trials, with a total of 703 nondepressed stroke patients, found that ADs prophylaxis was associated with a signifi cant reduction in the occurrence rate of newly developed poststroke depression (12.54% in the treated group vs 29.17% in control group) (Chen et al 2007) .
Length of treatment
At present, there is no scientifi c evidence regarding the optimal length of treatment of PSD. Many of the available trials terminate at six weeks, but withdrawal at this stage may result in relapse. In a recent review, Turner-Stokes and Hassan (2002) recommended carrying on AD treatment for 4-6 months, followed by slow withdrawal. The same length of AD is recommended by the Italian Guidelines for stroke management SPREAD (Stroke Prevention and Awareness Diffusion), but the power of this recommendation is weak (grade GPP, based on the clinical experience of the guideline development group, without research evidence) (SPREAD 2005) .
Conclusions
Presently, there are still too many questions about PSD and too few answers. Crucial unresolved issues are essentially related to correct diagnostic and therapeutic approaches. There is clear evidence that an AD treatment may improve depression but it is unable to produce a full clinical remission or prevent the onset of diagnosable depressive illness. Moreover, data available regarding the choice or the length of optimal treatment are still not conclusive.
Because the benefi ts of AD therapy are potentially great, not only on mood but also on functional recovery, there is a pressing need for further research in this area of stroke medicine.
